GLP-1 medications
GLP-1s or Glucagon-like peptide-1 receptor agonists are medicines that help people feel fuller by mimicking a natural hormone released after eating. Some newer medicines, like Mounjaro, also act on a second hormone involved in appetite and blood sugar control. They are licensed to support care of patients with type 2 diabetes or obesity. There are strict criteria for their use in the NHS and many patients seek them privately.
We do not always get informed about private medications and some private clinics are unaware of other medication their patients are taking. This leads to a risk that important medications are not absorbed properly and do not work well. This is particularly important for women taking oral hormonal contraception or oral HRT medicines.
The British Menopause Society recommend that women using GLP-1s move to a non-oral form of progesterone as part of their HRT - i.e patch or IUS coil such as Mirena. If this is not possible/ideal then it is important to increase the dose of progestogen/progesterone at initiation of the GLP-1 for 4 weeks and maintain higher dose for 4 weeks after any dose increase.
The College of Sexual and Reproductive Healthcare recommend that women using Mounjaro (tirzepatide) and oral hormonal contraception using barrier methods such as condoms to reduce the risk of pregnancy and consider moving to a non-oral form of contraception.
"If you are using tirzepatide you should use a barrier method of contraception (e.g. condoms) in addition to your pill for four weeks after starting the medication, and for four weeks after any increase in dose. This is because tirzepatide works slightly differently to the other GLP-1 agonists. Alternatively, you may wish to consider another (non-oral) method of contraception whilst using tirzepatide. There is currently no evidence that semaglutide, exenatide, liraglutide, dulaglutide or lixisenatide reduce the effectiveness of oral contraception (i.e. the combined pill, or the progestogen only pill/ “mini-pill”)".